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Background: Neurofibrillary tangles (NFTs) made up of hyper-
phosphorylated tau are the hallmark of Alzheimer’s disease
(AD) and related tauopathies. Hyperphosphorylation of tau is
responsible for its loss of function, gain of toxicity and its aggre-
gation to form NFTs. Injection of misfolded tau seeds into mouse
brain induces phosphorylated tau aggregation, but the nature of
tau phosphorylation in pathologic tau seeded pathology is unclear.
Methods: Hyperphosphorylated and oligomeric tau isolated from
AD brain (AD P-tau) was injected unilaterally into hippocampus
of the human tau transgenic mice and tau knockout mice. Tau
phosphorylation, the expression of tau kinases and tau phospha-
tases in the hippocampi and cortices were analyzed by Western
blots. Results: We found that in addition to tau pathology, AD
P-tau induced hyperphosphorylation of tau at Ser202/Thr205,
Thr212, Ser214, Thr217, Ser262, and Ser422 in the ipsilateral hip-
pocampus and at Ser422 in the contralateral hippocampus and in
the ipsilateral cortex. AD P-tau induced AD-like high molecular
weight aggregates of tau that was SDS- and reducing agent-resis-
tant in the injected hippocampus. There were no detectable alter-
ations in levels of tau phosphatases or tau kinases in AD P-tau-
injected brains. Furthermore, we found that hyperphosphorylated
tau was easier to be captured by AD P-tau and that aggregated tau
was more difficult to be dephosphorylated than non-aggregated
tau by protein phosphatase 2A (PP2A). Conclusions: Based on
these findings, we speculate that AD P-tau seeds capture hyper-
phosphorylated tau to form aggregation, which leads to resistance
to dephosphorylation by PP2A, resulting in tau hyperphosphory-
lation and tau pathology.P4-153 LOSS OF BILIVERDIN REDUCTASE-AFAVORS TAU HYPER-PHOSPHORYLATION
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during the progression of Alzheimer disease (AD). Akt is one of
the main kinases inhibiting GSK-3band its activation occurs in
response to neurotoxic stimuli including, i.e., oxidative stress. Bili-
verdin reductase-A (BVR-A) is a scaffold protein favoring the Akt-
mediated inhibition of GSK-3b. Reduced BVR-A levels along with
increased oxidative stress were observed early in the hippocampus
of 3xTg-AD mice (at 6 months), thus suggesting that loss of BVR-A could be a limiting factor in the oxidative stress-induced Akt-
mediated inhibition of GSK-3bin AD. Methods: We evaluated
changes of BVR-A, Akt, GSK-3b, oxidative stress and Tau phos-
phorylation levels: (a) in brain from young (6-months) and old
(12-months) 3xTg-AD mice; and (b) in post-mortem inferior pari-
etal lobule (IPL) samples from amnestic mild cognitive impairment
(MCI), from AD and from age-matched controls. Furthermore,
similar analyses were performed in vitro in cells lacking BVR-A
and treated with H2O2. Results: Reduced BVR-A levels along
with: (a) increased oxidative stress; (b) reduced GSK-3binhibition;
and (c) increased Tau Ser404 phosphorylation (target of GSK-
3bactivity) without changes of Akt activation in young mice,
were observed. Similar findings were obtained in MCI, consistent
with the notion that this is a molecular mechanism disrupted in hu-
mans. Interestingly, cells lacking BVR-A and treated with H2O2
showed reduced GSK-3binhibition and increased Tau Ser404 phos-
phorylation, which resulted from a defect of Akt and GSK-3bphys-
ical interaction. Reduced levels of Akt/GSK-3bcomplex were
confirmed in bothyoung 3xTg-AD and MCI brain. Conclusions: We
demonstrated that loss of BVR-A impairs the neuroprotective Akt-
mediated inhibition of GSK-3bin response to oxidative stress, thus
contributing to Tau hyper-phosphorylation in early stage AD. Such
changes potential provides promising therapeutic targets for this
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protein involved in shuttling ubiquitinated substrates to the protea-
some for degradation and modulating autophagy. UBQLN2 has
been implicated in neurodegenerative disease due to its accumula-
tion in neuropathological deposits and its potential role in regu-
lating protein dyshomeostasis common across different
neurodegenerative disorders. The relationship of UBQLN2 to one
of the most common aggregating proteins in disease, tau, is un-
known.Methods: To determine the relevance of UBQLN2 dysregu-
lation to human disease, we measured levels of soluble and
insoluble UBQLN2 in human tauopathy brain tissue. To evaluate
whether UBQLN2 regulates tau clearance, we first assessed levels
of tau in human embryonic kidney-293 cells with and without
UBQLN2. The ability of UBQLN2 to regulate other common ag-
gregation-prone disease proteins, including alpha-synuclein was
also evaluated. To determine whether UBQLN2 acts on tau in
vivo, tau transgenic mice were crossed with UBQLN2 transgenic
and knockout mice. Results: Co-expressed UBQLN2 markedly
lowered levels of tau. Conversely, knockdown of UBQLN2
significantly elevated levels of tau. In contrast, a highly homolo-
gous protein, UBQLN1, did not exhibit the same ability to decrease
tau levels. UBQLN2 overexpression in vivo was associated with
decreased levels of insoluble tau. The possibility that UBQLN2
also undergoes alterations in disease was evidenced by the fact
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Conclusions: Our findings highlight a new role for UBQLN2—but
not UBQLN1—in managing levels of tau and other neurodegener-
ative disease proteins in the brain. However, increased insoluble
UBQLN2 correlated with pathological tau accumulation suggest
that UBQLN2 may be dysfunctional in tauopathies due to its
intrinsic aggregation or accumulation in disease aggregates.P4-155 INCREASED TAU PROTEIN TOMAPTMRNA RATIOS AND DECREASED LEVELS
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Background: Mutations in the gene that encodes the microtubule-
associated protein tau (MAPT) cause frontotemporal dementia
spectrum disorders (FTDs) but not Alzheimer’s disease (AD).
However, the rare A152T-variant of tau increases the risk for
both AD and FTDs by an odds ratio of roughly 2. Understanding
the underlying mechanisms could identify pathogenic convergence
points between these conditions. We previously showed that trans-
genic mice expressing A152T-variant human tau protein (hTau-
A152T) in glutamatergic forebrain neurons had lower human
MAPT mRNA levels than transgenic mice expressing comparable
levels of wildtype human tau protein (hTau-WT). hTau-A152T
mice also had lower cerebral levels of hTau fragments. In contrast,
other groups reported higher levels of tau fragmentation in iPS cell-
derived neurons from A152T carriers than non-carriers. Here, we
assessed which of these models more accurately predicts MAPT
expression and tau processing in the human condition. Methods:
Frozen postmortem brain tissues from human A152T carriers (n
¼ 15) and non-carriers (n ¼ 17) matched for age, sex, and autopsy
diagnosis (AD, FTLD, PSP, or CBD) were compared by western
blot analysis and quantitative RT-PCR.Results: Across tauopathies,
human carriers and non-carriers had similar levels of full-length tau
protein in sarkosyl-soluble fractions. In contrast, MAPT mRNA
levels were roughly 50% lower in carriers than non-carriers, indi-
cating that carriers have an increased tau protein to MAPT
mRNA ratio. Levels of tau fragments were also significantly lower
in carriers than non-carriers. These results are remarkably similar to
those we obtained in transgenic mice expressing MAPT cDNAs
from a heterologous promoter (EMBO Rep. 17: 530–551). Conclu-
sions: Taken together, our findings suggest that the A152T substitu-
tion interferes with the degradation of tau at the protein level and
that the reduced MAPT mRNA levels in carriers reflect a compen-
satory adjustment in gene expression. Although we consider this
interpretation most plausible, alternative mechanisms affecting
gene expression or mRNA turnover have not yet been excluded.
Ongoing studies aim to identify the mechanisms by which the
A152T substitution reduces both tau fragmentation and MAPT
mRNA levels and to elucidate the processes by which hTau-
A152T increases the risk of diverse tauopathies. Supported by the
Tau Consortium.P4-156 DISCOVERY OF NOVEL SMALLMOLECULE THERAPEUTICS FOR
ALZHIEMER’S DISEASE BY TARGETING
STERIC ZIPPERS INVOLVED IN TAU
AGGREGATIONMarcin I. Apostol1, Ashley Wright1, Matthew Graf1, Jon Scherrer1,
Ken Kosik2, James Treanor3, 1ADRx Inc., Thousand Oaks, CA, USA;
2University of California, Santa Barbara, Santa Barbara, CA, USA; 3ADRx
Inc, Thousand Oaks, CA, USA. Contact e-mail: marcin@adrxpharma.com
Background: Frontotemporal dementia and Alzheimer’s disease
(AD) are progressive neurodegenerative diseases characterized
in part by aggregation of the tau protein. At the molecular and
cellular levels the aggregation of tau leads to the formation of
neurofibrillary tangles (NFTs) that cause a loss of neuronal con-
nectivity, initiate neurodegeneration, and result in the cognitive
decline that is the hallmark of the disease. Tau aggregation is
dependent on two highly aggregation-prone hexapeptide seg-
ments or "steric zippers"–VQIVYK and VQIINK–that are located
in the repeat domains in the tau protein.Methods: ADRx has used
a structure-based approach to design and optimize novel peptidic
Tau Aggregation Inhibitors (pTAI) that bind to these segments in
their aggregation-competent conformation. Here we show that
pTAIs prevent tau aggregation both in biochemical and cellular
assays as well as in transgenic rTg4510 mice using a viral delivery
approach. ADRx has leveraged this approach to develop a targeted
competition assay to identify small molecule compounds that
mimic the properties of pTAIs and allow a more facile develop-
ment path for delivery as a therapeutic. Results: A high-
throughput screen of over 200,000 compounds has successfully
identified multiple chemotypes that selectively disrupt the interac-
tion of a potent pTAI to aggregated Tau. Similar to the pTAIs,
these small molecules prevent aggregation of tau in ThT-based
and cellular reporter assays. The unique nature of this competition
assay has identified molecules that promise a level of specificity
and potency superior to aggregation inhibitors identified by other
means. Conclusions: We believe that these represent an exciting
new set of molecules that have the potential to become the first
therapeutics specifically targeting steric zippers to prevent tau ag-
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implicated in neurodegeneration of Alzheimer’s disease. We have
shown that tau P301L has a higher binding affinity, than WT tau,
to Fyn. However, the role of Fyn in mediating disease pathogeneses
in tauopathies, where Abeta protein is absent, is still not very well
understood. Methods: We have used the somatic brain transgenic
technique to produce tauopathy mouse models where AAV vectors
deliver human tau P301L to the brains of newborn Fyn KO andWT
mice. Fyn KO mice with severe hydrocephalus were identified by
MRI and not used for comparisons. Mice were harvested at 6
months, examining tau phosphorylation at S199/S202 and Y18.
Behavioral studies were also performed, with un-injected Fyn
